39.5 BILLION TENGE AND 300 JOBS IN SHYMKENT

A large-scale expansion of Polpharma Santo pharmaceutical production is set to begin in Shymkent with private investment totaling 39.5 billion tenge. The project is being implemented jointly with the Ministry of Health and JSC “Khimpharm” and is aimed at increasing the share of domestically produced medicines in the national market.

Prime Minister Olzhas Bektenov signed the agreement on the project’s implementation. Around 300 new jobs are expected to be created as part of the expansion. Investment funds will be directed toward construction of new production facilities, procurement of modern equipment, and development of research programs.

The first phase of the enterprise is planned to be completed by the end of 2029. Once operational, the new capacities will enable production of 38 types of medicines. These include treatments for oncological, cardiovascular, infectious, and chronic diseases, including tuberculosis. Production will comply with international quality standards.

The project is expected to strengthen Kazakhstan’s pharmaceutical security, expand the technological base of the industry, and increase the country’s export potential. It will also contribute to reducing dependence on imports in certain categories of medicines.

The editors are not responsible for the content and accuracy of materials taken, sent or received from other sources. The publication of such materials is carried out solely for informational purposes and does not imply automatic support or approval of their content.